适应症-话题@MedSci

#适应症#

219篇内容 | 3050人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336861, encodeId=f4b4133686134, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病, objectType=article, longId=293458, objectId=f26a2934582a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26a2934582a, replyNumber=0, likeNumber=81, createdTime=2022-01-07, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26a2934582a, moduleTitle=再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26a2934582a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336859, encodeId=16cb13368597d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, objectType=article, longId=293239, objectId=482e29323925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482e29323925, replyNumber=0, likeNumber=90, createdTime=2022-01-03, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482e29323925, moduleTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482e29323925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336860, encodeId=54d71336860a4, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, objectType=article, longId=293200, objectId=ccdc2932002c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccdc2932002c, replyNumber=0, likeNumber=97, createdTime=2022-01-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccdc2932002c, moduleTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccdc2932002c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336858, encodeId=eae41336858fd, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=美国FDA扩大镰状细胞病药物Oxbryta的适应症, objectType=article, longId=292406, objectId=ce1b292406d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1b292406d4, replyNumber=0, likeNumber=77, createdTime=2021-12-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1b292406d4, moduleTitle=美国FDA扩大镰状细胞病药物Oxbryta的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1b292406d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336857, encodeId=ce42133685e48, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, objectType=article, longId=259943, objectId=cceb25994367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceb25994367, replyNumber=0, likeNumber=92, createdTime=2021-12-12, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceb25994367, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cceb25994367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336856, encodeId=df87133685695, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=君实生物特瑞普利单抗新增两项适应症纳入国家医保目录, objectType=article, longId=221523, objectId=b747221523b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b747221523b7, replyNumber=0, likeNumber=107, createdTime=2021-12-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b747221523b7, moduleTitle=君实生物特瑞普利单抗新增两项适应症纳入国家医保目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b747221523b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336855, encodeId=b224133685598, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, objectType=article, longId=221354, objectId=a16422135482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16422135482, replyNumber=0, likeNumber=104, createdTime=2021-12-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16422135482, moduleTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16422135482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336854, encodeId=072b1336854fa, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=12 岁以下儿童肺移植后的适应症和结果：16 年的单中心经验, objectType=article, longId=221239, objectId=a74322123907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74322123907, replyNumber=0, likeNumber=74, createdTime=2021-11-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74322123907, moduleTitle=12 岁以下儿童肺移植后的适应症和结果：16 年的单中心经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74322123907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336864, encodeId=fe34133686416, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代, objectType=article, longId=290364, objectId=55a82903641f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55a82903641f, replyNumber=0, likeNumber=106, createdTime=2021-11-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55a82903641f, moduleTitle=「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55a82903641f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336853, encodeId=e000133685336, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, objectType=article, longId=217708, objectId=bfcd21e7083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfcd21e7083b, replyNumber=0, likeNumber=73, createdTime=2021-09-28, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfcd21e7083b, moduleTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfcd21e7083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336852, encodeId=e787133685291, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=JAAD：放射疗法治疗皮肤癌的适应症, objectType=article, longId=216482, objectId=ffe0216482f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe0216482f3, replyNumber=0, likeNumber=78, createdTime=2021-09-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe0216482f3, moduleTitle=JAAD：放射疗法治疗皮肤癌的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe0216482f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336851, encodeId=ee05133685122, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, objectType=article, longId=216300, objectId=4bad2163009e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bad2163009e, replyNumber=0, likeNumber=87, createdTime=2021-08-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bad2163009e, moduleTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bad2163009e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336850, encodeId=172d133685005, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤, objectType=article, longId=213747, objectId=dec0213e4729, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dec0213e4729, replyNumber=0, likeNumber=65, createdTime=2021-07-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dec0213e4729, moduleTitle=宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dec0213e4729)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336849, encodeId=baab133684920, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, objectType=article, longId=213744, objectId=3257213e448e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3257213e448e, replyNumber=0, likeNumber=51, createdTime=2021-07-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3257213e448e, moduleTitle=罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3257213e448e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336848, encodeId=7b62133684882, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生, objectType=article, longId=210711, objectId=8b33210e118c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b33210e118c, replyNumber=0, likeNumber=95, createdTime=2021-05-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b33210e118c, moduleTitle=罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b33210e118c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336847, encodeId=339b133684e19, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, objectType=article, longId=209983, objectId=86f62099835f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86f62099835f, replyNumber=0, likeNumber=100, createdTime=2021-04-16, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86f62099835f, moduleTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86f62099835f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336846, encodeId=230313368466e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=不完美的治愈之光？奥希替尼辅助治疗适应症获批的几点思考, objectType=article, longId=209777, objectId=45ef209e777b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45ef209e777b, replyNumber=0, likeNumber=83, createdTime=2021-04-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45ef209e777b, moduleTitle=不完美的治愈之光？奥希替尼辅助治疗适应症获批的几点思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45ef209e777b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336845, encodeId=7e4213368454a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=史赛克骨科手术机器人获批全膝关节置换适应症, objectType=article, longId=209537, objectId=bbe920953ee4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbe920953ee4, replyNumber=0, likeNumber=92, createdTime=2021-04-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbe920953ee4, moduleTitle=史赛克骨科手术机器人获批全膝关节置换适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbe920953ee4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336844, encodeId=9ebf1336844cc, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=K药在欧盟获批儿科适应症, objectType=article, longId=208754, objectId=64a7208e54b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64a7208e54b4, replyNumber=0, likeNumber=60, createdTime=2021-03-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64a7208e54b4, moduleTitle=K药在欧盟获批儿科适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64a7208e54b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336842, encodeId=15a4133684247, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=K药在欧盟获批儿科适应症, objectType=article, longId=208695, objectId=0ef7208695b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef7208695b9, replyNumber=0, likeNumber=92, createdTime=2021-03-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef7208695b9, moduleTitle=K药在欧盟获批儿科适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef7208695b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病

2022-01-07

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症

2022-01-03

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测

2022-01-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

美国FDA扩大镰状细胞病药物Oxbryta的适应症

2021-12-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理

2021-12-12

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

君实生物特瑞普利单抗新增两项适应症纳入国家医保目录

2021-12-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市

2021-12-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

12 岁以下儿童肺移植后的适应症和结果：16 年的单中心经验

2021-11-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代

2021-11-10

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗

2021-09-28

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

JAAD：放射疗法治疗皮肤癌的适应症

2021-09-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗

2021-08-27

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

宜明昂科CD47xHER2双特异性抗体获批临床，适应症为HER2表达的晚期实体瘤

2021-07-06

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

罗氏PD-1/LAG-3双特异性抗体在中国申报临床，有望用于转移性黑色素瘤、非小细胞肺癌、食管鳞状细胞癌、晚期肝癌多种适应症治疗

2021-07-06

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生

2021-05-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批

2021-04-16

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

不完美的治愈之光？奥希替尼辅助治疗适应症获批的几点思考

2021-04-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

史赛克骨科手术机器人获批全膝关节置换适应症

2021-04-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

K药在欧盟获批儿科适应症

2021-03-22

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

K药在欧盟获批儿科适应症

2021-03-20

科室
- - 订阅+
  - 更多科室
工具
服务